Inhaled Iloprost in the Treatment of Patients With Pulmonary Hypertension up to 4 Years
Status:
Completed
Trial end date:
2018-06-18
Target enrollment:
Participant gender:
Summary
This is an open-label, uncontrolled, prospective long-term observation of Specific Drug in
the treatment of patients with pulmonary hypertension up to 4 years. 160 patients with
primary (idiopathic and familial) pulmonary hypertension (PH) or pulmonary arterial
hypertension (PAH) due to scleroderma with New York Heart Association (NYHA) functional class
and exercise capacity, defined as class III and IV planned to enroll. Efficacy, safety and
tolerability of the drug and the survival of the patients will be observed.